ArticlePloS one2013
Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers.Cancer research and treatment · 2025Article
- Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection.Viruses · 2024Article
- Feasibility and effectiveness of second-line chemotherapy with mitomycin C in patients with advanced penile cancer.Frontiers in urology · 2023Article
- Emerging Therapies in Penile Cancer.Frontiers in oncology · 2022Review
- A Personalized Therapeutics Approach Using anFrontiers in oncology · 2021Article
- Noncanonical Cell Death Induction by Reassortant Reovirus.Journal of virology · 2020Article
- SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer.American journal of cancer research · 2020Article
- The molecular pathogenesis of penile carcinoma-current developments and understanding.Virchows Archiv : an international journal of pathology · 2019Review
- Current understanding of reovirus oncolysis mechanisms.Oncolytic virotherapy · 2018Review
- Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.Translational andrology and urology · 2017Review
- Current Management Strategy for Penile Cancer and Future Directions.Current oncology reports · 2017Review
- Review
- Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.Clinical genitourinary cancer · 2016Article
- Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.Frontiers in pharmacology · 2016Article
- A phase 1 study of ABT-806 in subjects with advanced solid tumors.Investigational new drugs · 2015Article
- Article
- Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.Medical oncology (Northwood, London, England) · 2013Article
- [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].Der Urologe. Ausg. A · 2013Article
- Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Penile Squamous Cell Carcinoma (SCC) is a rare cancer with poor prognosis and limited response to conventional chemotherapy. The genetic and epigenetic alterations of Epidermal Growth Factor Receptor (EGFR)-RAS-RAF signaling in penile SCC are unclear. This study aims to investigate four key members of this pathway in penile SCC. We examined the expression of EGFR and RAS-association domain family 1 A (RASSF1A) as well as the mutation status of K-RAS and BRAF in 150 cases of penile SCC. EGFR and RASSF1A expression was evaluated by immunohistochemistry. KRAS mutations at codons 12 and 13, and the BRAF mutation at codon 600 were analyzed on DNA isolated from formalin fixed paraffin embedded tissues by direct genomic sequencing. EGFR expression was positive in all specimens, and its over-expression rate was 92%. RASSF1A expression rate was only 3.42%. Significant correlation was not found between the expression of EGFR or RASSF1A and tumor grade, pT stage or lymph node metastases. The detection of KRAS and BRAF mutations analysis was performed in 94 and 83 tumor tissues, respectively. We found KRAS mutation in only one sample and found no BRAF V600E point mutation. In summary, we found over-expression of EGFR in the majority cases of penile SCC, but only rare expression of RASSF1A, rare KRAS mutation, and no BRAF mutation in penile SCC. These data suggest that anti-EGFR agents may be potentially considered as therapeutic options in penile SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.